[Chinese expert consensus on management of dyslipidemia in the elderly]

Zhonghua Nei Ke Za Zhi. 2022 Oct 1;61(10):1095-1118. doi: 10.3760/cma.j.cn112138-20220407-11251.
[Article in Chinese]

Abstract

Dyslipidemia is an important risk factor of atherosclerotic cardiovascular disease (ASCVD). Statins delay the occurrence and development of ASCVD, and reduce the risk of cardiovascular events and death. Due to safety concerns, there exist insufficient use of lipid-lowering agents and a high withdrawal rate of the agents in the elderly. To promote the prevention and treatment of ASCVD, this expert consensus is issued and focuses on the management of dyslipidemia of Chinese elderly basing on the clinical evidence of the use of lipid-lowering drugs by the elderly, and the lipid management guidelines and expert consensus recommendations at home and abroad.

血脂异常是导致动脉粥样硬化性心血管疾病(ASCVD)的重要危险因素,他汀类药物延缓ASCVD的发生、发展并降低心血管事件及死亡的风险。由于对安全性的担忧,老年人调脂药物使用不足、停药率高。本专家共识依据老年人使用调脂药物的临床证据,参考国内外血脂管理指南及专家共识推荐,对我国老年人的血脂异常提出管理建议,旨在促进我国老年ASCVD防治工作。.

MeSH terms

  • Aged
  • Atherosclerosis*
  • Cardiovascular Diseases* / prevention & control
  • China
  • Cholesterol, LDL
  • Consensus
  • Dyslipidemias* / drug therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors